Treatment of a Laboratory-Acquired Sabiá Virus Infection

Barry, Michèle; Russi, Mark; Armstrong, Lori; Geller, David S.; Tesh, Robert B.; Dembry, Louise‐Marie; Gonzalez, Jean‐Paul; Khan, Ali S.; Peters, C. J.

doi:10.1056/nejm199508033330505

Cited by 107 publications

(52 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intravenous ribavirin has shown efficacy against Lassa fever in high-risk patients (37), although its use can be associated with dose-limiting anemia (47). Ribavirin has also been used to treat isolated infections with the New World arenaviruses Junín virus (JUNV) (19), Machupo virus (MACV) (30), and Sabiá virus (6), although extensive clinical data are lacking. A vaccine candidate for Argentine hemorrhagic fever (JUNV) has demonstrated good efficacy among agricultural workers in South America (34), and several Lassa fever vaccine candidates have demonstrated efficacy in nonhuman primate models (21,22,27).…”

mentioning

confidence: 99%

Identification of a Broad-Spectrum Arenavirus Entry Inhibitor

Larson

Dai

Hosack

et al. 2008

J Virol

124

150

View full text Add to dashboard Cite

mentioning

confidence: 99%

Identification of a Broad-Spectrum Arenavirus Entry Inhibitor

Larson

Dai

Hosack

et al. 2008

J Virol

124

150

View full text Add to dashboard Cite

“…Based on this case, it could be suggested that ribavirin could be used to treat future cases of SABV infection 23 . Supporting this, evidence exists that ribavirin can be used to treat Argentine hemorrhagic fever, which is caused by the Junin virus 24 .…”

Section: Four Documented Cases Of Sabiá Virus Infectionmentioning

confidence: 96%

“…Clinical and experimental evidence has shown that the antiviral drug ribavirin can be used to treat SABV infection 23,24 . As Radoshitzky et al 25 have suggested, antiviral drugs focused on viral transcription and replication can work through different routes.…”

Section: Basic Aspects Of the Sabiá Virusmentioning

confidence: 99%

“…After centrifugation of approximately 240mL supernatant from a tissue culture infected with SABV, the researcher realized that the tube used for the centrifugation was broken, and that a large portion of container contents (approximately 100mL) had leaked into the rotor of the centrifuge. The infection possibly happened by a leaking rotor or during the cleaning/opening procedure of the centrifuge, although the researcher was not directly exposed to the leaked content and used personal protective equipment 8,23,28,29 . Human error was recognized as the principal factor causing this incident 30 .…”

Section: Four Documented Cases Of Sabiá Virus Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Keeping track of hidden dangers - The short history of the Sabiá virus

Ellwanger

2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Emerging infectious diseases are a global threat. In countries like Brazil, where biodiversity is high and public health conditions in terms of infrastructure and medical care are often precarious, emerging diseases are particularly worrisome. The lack of monitoring strategies to identify pathogens with the potential to cause outbreaks or epidemics is another problem in Brazil and other developing countries. In this article, we present the history of the Sabiá virus (SABV), a pathogen that was described in the 1990s in Brazil. Several aspects of the biology and ecology of the SABV remain unknown. The SABV has the potential to cause hemorrhagic fever in humans. To date, four cases of human infections have been reported worldwide; two were naturally acquired (both in Brazil), whereas the other two were linked to occupational exposure in the laboratory environment (one in Brazil and one in the USA). In this review, we summarize the basic biological and ecological characteristics of the SABV. This is the first work to gather all available data on the historical aspects involving the cases of SABV infection along with an update on its characteristic features.

show abstract

“…It is widely considered the most efficacious drug in arenavirus infections, including LASV and other NW arenaviruses. [25][26][27][28] The mechanism of action in arenavirus infections is not entirely clear, but it seemingly targets different steps in the life cycle. 29 In the LUJV outbreak, oral ribavirin was briefly attempted in Patient 3, and then early in the illness of Patient 5 (ID-1; 2 g loading and 1 g q 6 hours thereafter).…”

Section: Treatmentmentioning

confidence: 99%

Lujo virus: current concepts

Sewlall¹,

Pawęska²

2017

VAAT

View full text Add to dashboard Cite

Lujo virus (LUJV), a novel Old World arenavirus, was found to cause a fulminant viral hemorrhagic fever syndrome in an outbreak in 2008. The primary patient was from Lusaka, Zambia, and subsequent nosocomial transmission occurred to four other patients in Johannesburg, South Africa, hence the name Lujo virus. Like all arenaviruses, LUJV is a segmented, single-stranded, negative-sense RNA virus. Genomic sequencing confirmed that LUJV G1 glycoprotein was novel, diverse and genetically equidistant from other arenaviruses. A clinical syndrome resembling severe, fulminant Lassa virus infection was responsible for a high case fatality rate of 80% (4/5 cases). This review describes briefly the clinical course of the disease, laboratory findings and diagnosis. Recent studies address the current aspects of epidemiology, pathophysiology and treatments, specifically comparing with Lassa virus.

show abstract

Treatment of a Laboratory-Acquired Sabiá Virus Infection

Cited by 107 publications

References 4 publications

Identification of a Broad-Spectrum Arenavirus Entry Inhibitor

Identification of a Broad-Spectrum Arenavirus Entry Inhibitor

Keeping track of hidden dangers - The short history of the Sabiá virus

Lujo virus: current concepts

Contact Info

Product

Resources

About